Tegavivint suppresses chemotherapy-resistant and metastatic osteosarcoma by disturbing β-catenin-TBL1 binding8, and SUMOylation of TBL1/TBLR1 promotes the migration and invasion of bladder cancer cells9. Here, TBL1X is linked to urinary bladder carcinoma.